Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunovant, Inc. (Nasdaq: IMVT) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view into its operations as a clinical-stage immunology company. These documents complement Immunovant’s focus on developing FcRn-targeting monoclonal antibodies, including IMVT-1402 and batoclimab, for IgG-mediated autoimmune diseases.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q, where Immunovant discusses research and development activities, general and administrative expenses, net losses and cash balances. These filings also describe the company’s single operating segment, risk factors related to clinical development and financing needs, and its relationship with controlling stockholder Roivant Sciences Ltd.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have addressed quarterly financial results, leadership changes, executive employment agreements, separation arrangements with senior officers, clinical program updates in Graves’ disease and other indications, and outcomes of the company’s annual meeting of stockholders. These filings can include or reference press releases with detailed clinical and financial information.
Immunovant’s proxy statements on Schedule 14A offer insight into corporate governance, board composition, executive compensation and stockholder voting matters. The definitive proxy statement also outlines the company’s corporate history, including its business combination that resulted in the current Immunovant, Inc. structure.
Through Stock Titan, users can access these SEC filings as they are made available on EDGAR, along with AI-powered summaries that help explain key points in lengthy documents. This includes highlighting major changes in clinical strategy, financing transactions, governance decisions and other disclosures that shape the risk and opportunity profile for IMVT.
Immunovant (IMVT) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $126.5 million for the quarter and $247.1 million for the six-month period, reflecting increased investment in clinical programs. Loss per share was $0.73 for the quarter and $1.43 year-to-date.
Research and development expenses rose to $114.2 million in the quarter (from $97.3 million), driven by potentially registrational trials across endocrine (Graves’ disease), neurology (myasthenia gravis, CIDP), rheumatology (difficult-to-treat RA, Sjögren’s), and a proof-of-concept in dermatology (cutaneous lupus). General and administrative expenses declined to $17.5 million from $18.5 million.
Cash and cash equivalents were $521.9 million, with operating cash outflows of $219.9 million for the six months. Management states this balance is expected to fund announced indications through the Graves’ disease readout in 2027. Shares outstanding were 174,532,710 as of September 30, 2025. The company has an unused at-the-market program of up to $150.0 million and a remaining $39.1 million minimum obligation for batoclimab manufacturing.
Immunovant, Inc. furnished an 8-K announcing a press release with financial results for its fiscal second quarter and six months ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished, not deemed “filed” under the Exchange Act, and will not be incorporated by reference in other SEC filings. The report was signed by Chief Financial Officer Tiago Girao.
Immunovant (IMVT) insider filing: the Chief Medical Officer reported selling 2,595 shares on October 22, 2025 at a weighted average price of $19.03 (range $19.03–$19.20). The sale was a mandated “sell to cover” to satisfy tax withholding tied to the vesting and settlement of RSUs.
After the transaction, the reporting person beneficially owns 217,958 shares. Footnotes note that 6,250 of a previously granted 100,000 RSUs vested on October 17, 2025.
Immunovant, Inc. (IMVT) disclosed an insider transaction by its Chief Technology Officer, Jay Stout. On 10/22/2025, he sold 2,520 shares of common stock at a weighted average price of $19.03 per share, with trades executed between $19.03–$19.23. The filing states this was a mandated “sell to cover” to satisfy tax withholding arising from the vesting and settlement of 6,250 RSUs on 10/17/2025, part of a 100,000 RSU grant awarded on 04/17/2023, and was not a discretionary transaction.
Following the sale, Stout beneficially owned 200,814 shares, held directly.
Insider sale to cover taxes: The Chief Medical Officer, Michael Geffner, sold 1,272 shares of Immunovant common stock on 10/08/2025 as a sell-to-cover to satisfy tax withholding tied to vested restricted stock units. The weighted average sale price was $16.30 per share (individual trades ranged $16.06–$16.48).
Geffner was granted 54,978 RSUs on 4/2/2024; 3,436 of those RSUs vested on 10/2/2025. After the reported sale, the reporting person beneficially owned 220,553 shares. The filing states the sale was mandated by the issuer's sell-to-cover tax election and not a discretionary transaction.
On 10/08/2025, Chief Technology Officer Jay S. Stout reported the sale of 1,585 shares of Immunovant, Inc. (IMVT) common stock at a weighted average price of $16.3 per share. The shares sold were from the vesting and settlement of restricted stock units granted on 04/02/2024; 3,436 RSUs vested on 10/02/2025. The sale was executed as a mandatory "sell to cover" to satisfy tax withholding and was not a discretionary sale by the reporting person. After the reported transactions, the reporting person beneficially owned 203,334 shares.
Immunovant, Inc. reported that it issued a press release on September 3, 2025 providing an update on its Graves’ Disease development program. The press release is included as an exhibit and is incorporated by reference.
The company also posted an investor presentation on its website covering an update on its Graves’ Disease proof-of-concept study and plans to host a conference call and webcast at 4:30 p.m. E.D.T. to discuss remission data from the trial. The presentation used for this call is filed as a separate exhibit.
Immunovant, Inc. reported voting results from its 2025 Annual Meeting of Stockholders held on August 27, 2025. A total of 165,885,480 shares of common stock and Series A preferred stock were represented, about 97% of the shares entitled to vote, indicating very high participation.
Stockholders elected Jacob Bauer, Douglas Hughes and Robert Susman to the Board of Directors until the 2026 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending March 31, 2026, with 165,422,634 votes for, 7,237 against and 455,609 abstaining.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of Immunovant’s named executive officers, with 158,995,232 votes for, 1,244,731 against, 4,437 abstaining and 5,641,080 broker non-votes.
Immunovant is a clinical-stage immunology company advancing two anti-FcRn antibodies, IMVT-1402 and batoclimab. For the quarter ended June 30, 2025 the company reported a net loss of $120.6 million versus $87.2 million a year earlier, driven by higher research and development ($101.2 million versus $75.5 million) and increased general and administrative expense ($26.0 million versus $18.8 million). Cash and cash equivalents totaled $598.9 million at quarter end, down from $714.0 million three months earlier, and cash used in operations was $117.4 million.
The company has initiated multiple potentially registrational IMVT-1402 trials across Graves disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sj f6grens disease and a CLE proof-of-concept study, and expects a Graves disease readout in 2027. Batoclimab Phase 3 top-line results in thyroid eye disease are expected in the second half of 2025. Contractual commitments include an estimated $43.1 million remaining minimum purchase obligation to Samsung and potential milestone payments under the HanAll license up to $420.0 million (after $32.5 million previously paid).
Immunovant, Inc. furnished an update on its business by issuing a press release with financial results for its fiscal first quarter ended June 30, 2025. The company reported these results publicly on August 11, 2025, and attached the press release as Exhibit 99.1.
The disclosure is made under the Results of Operations and Financial Condition section and is treated as furnished rather than filed, which limits certain legal liabilities. The report is signed on behalf of Immunovant by Chief Financial Officer Tiago Girao on August 11, 2025.